{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:45:34Z","timestamp":1790469934531,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ejca.2021.02.038","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T08:12:03Z","timestamp":1617351123000},"page":"235-248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program"],"prefix":"10.1016","volume":"149","author":[{"given":"Arsela","family":"Prelaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4345-3355","authenticated-orcid":false,"given":"Achille","family":"Bottiglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Proto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lo Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Signorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"De Toma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Viscardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Brambilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3484-9718","authenticated-orcid":false,"given":"Riccardo","family":"Lobefaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Nichetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Manglaviti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Occhipinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Labianca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Ganzinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"Gallucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Zilembo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella Francesca","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valter","family":"Torri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"de Braud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina C.","family":"Garassino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ejca.2021.02.038_bib1","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdt205","article-title":"Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)","volume":"24","author":"Dearden","year":"2013","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2021.02.038_bib2","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jtho.2017.04.003","article-title":"Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non\u2013small cell lung cancer","volume":"12","author":"Jenkins","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2021.02.038_bib3","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1158\/1535-7163.MCT-12-0620","article-title":"EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics","volume":"12","author":"Arcila","year":"2013","journal-title":"Mol Canc Therapeut"},{"issue":"1","key":"10.1016\/j.ejca.2021.02.038_bib4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.lungcan.2014.10.014","article-title":"HER2 gene mutations in non-small cell lung carcinomas: concurrence with her2 gene amplification and her2 protein expression and phosphorylation","volume":"87","author":"Suzuki","year":"2015","journal-title":"Lung Canc"},{"issue":"4","key":"10.1016\/j.ejca.2021.02.038_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.09.001","article-title":"Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity","volume":"36","author":"Robichaux","year":"2019","journal-title":"Canc Cell"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2021.02.038_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.9514","article-title":"Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients","volume":"38","author":"Le","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2021.02.038_bib7","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.9007","article-title":"Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions","volume":"37","author":"Janne","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2021.02.038_bib8","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.9512","article-title":"Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC)","volume":"38","author":"Park","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2021.02.038_bib9","first-page":"228","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Canc Oxf Engl 1990"},{"issue":"4","key":"10.1016\/j.ejca.2021.02.038_bib10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Contr Clin Trials"},{"issue":"7","key":"10.1016\/j.ejca.2021.02.038_bib11","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/annonc\/mdv186","article-title":"Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors","volume":"26","author":"Kris","year":"2015","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2021.02.038_bib12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/annonc\/mdv573","article-title":"Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort","volume":"27","author":"Mazi\u00e8res","year":"2016","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2021.02.038_bib13","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1016\/j.jtho.2019.08.443","article-title":"OA07.03 clinical outcome of non-small cell lung cancer with EGFR\/HER2 exon 20 insertions identified in the LC-SCRUM-Japan","volume":"14","author":"Udagawa","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2021.02.038_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.9513","article-title":"ECOG-ACRIN 5162: a phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions","volume":"38","author":"Piotrowska","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2021.02.038_bib15","doi-asserted-by":"crossref","first-page":"S282","DOI":"10.1016\/j.jtho.2019.08.567","article-title":"MA09.03 identification of mechanisms of acquired resistance to poziotinib in EGFR exon 20 mutant non-small cell lung cancer (NSCLC)","volume":"14","author":"Elamin","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2021.02.038_bib16","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.9504","article-title":"Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): interim results of DESTINY-Lung01","volume":"38","author":"Smit","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.02.038_bib17","first-page":"28","article-title":"Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study","volume":"109","author":"Lai","year":"2019","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2021.02.038_bib18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.9089","article-title":"Single-arm, phase II study of pyrotinib in advanced non-small cell lung cancer (NSCLC) patients with HER2 exon 20 mutation","volume":"37","author":"Gao","year":"2019","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2021.02.038_bib19","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-12-0912","article-title":"Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas","volume":"18","author":"Arcila","year":"2012","journal-title":"Clin Canc Res"},{"issue":"19","key":"10.1016\/j.ejca.2021.02.038_bib20","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in\u00a0lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"issue":"7511","key":"10.1016\/j.ejca.2021.02.038_bib21","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ejca.2021.02.038_bib22","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jtho.2015.10.025","article-title":"HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers","volume":"11","author":"Li","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2021.02.038_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy292.112","article-title":"A phase II study of trastuzumab monotherapy in pretreated patients with non-small cell lung cancers (NSCLCs) harboring HER2 alterations: HOT1303-B trial","volume":"29","author":"Kinoshita","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2021.02.038_bib24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jtho.2017.10.032","article-title":"A phase II study of trastuzumab emtansine in HER2-positive non\u2013small cell lung cancer","volume":"13","author":"Hotta","year":"2018","journal-title":"J Thorac Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921001465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921001465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:32:17Z","timestamp":1760733137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921001465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":24,"alternative-id":["S0959804921001465"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.02.038","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.02.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}